<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02239913</url>
  </required_header>
  <id_info>
    <org_study_id>BED IN 27</org_study_id>
    <nct_id>NCT02239913</nct_id>
  </id_info>
  <brief_title>Topiramate-Phentermine Combinations for Cocaine Dependence</brief_title>
  <official_title>Topiramate-Phentermine Combinations for Cocaine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kentucky</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the influence of topiramate (Topamax速) and phentermine (Adipex速),
      alone and in combination, on the reinforcing, subjective and physiological effects of
      cocaine.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reinforcing Effects</measure>
    <time_frame>Nine times over approximately five weeks inpatient admission.</time_frame>
    <description>The reinforcing effects of cocaine will be determined using a self-administration procedure in which subjects choose to take previously sampled doses.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective effects</measure>
    <time_frame>Nine times over approximately five weeks inpatient admission.</time_frame>
    <description>Subjects will complete subjective effects measures during nine sessions while they are admitted to our inpatient unit. These items will ask about drug effects and general mood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physiological Effects</measure>
    <time_frame>Daily over approximately five week inpatient admissions</time_frame>
    <description>Physiological measures will be completed daily while subjects are admitted to our inpatient unit. Physiological measures include temperature, heart rate and blood pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>Daily over approximately five weeks of inpatient admission</time_frame>
    <description>Subjects will complete a side effects questionnaire daily while they reside on the inpatient unit. Side Effects questions will query subjects about common effects of centrally active medications.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Cocaine Use Disorder</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and phentermine during placebo maintenance. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topiramate Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be maintained on the low topiramate dose. Subjects will be maintained on placebo and phentermine during maintenance on the low dose of topiramate. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topiramate Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be maintained on the high topiramate dose. Subjects will be maintained on placebo and phentermine during maintenance on the high dose of topiramate. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cocaine</intervention_name>
    <description>The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and topiramate.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Topiramate Dose 1</arm_group_label>
    <arm_group_label>Topiramate Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The pharmacodynamic effects of placebo will be determined during maintenance on placebo and topiramate.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Topiramate Dose 1</arm_group_label>
    <arm_group_label>Topiramate Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phentermine</intervention_name>
    <description>The pharmacodynamic effects of phentermine maintenance will be determined during maintenance on placebo and topiramate.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Topiramate Dose 1</arm_group_label>
    <arm_group_label>Topiramate Dose 2</arm_group_label>
    <other_name>Adipex速</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiramate</intervention_name>
    <description>The pharmacodynamic effects of chronic topiramate will be determined.</description>
    <arm_group_label>Topiramate Dose 1</arm_group_label>
    <arm_group_label>Topiramate Dose 2</arm_group_label>
    <other_name>Topamax速</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recent cocaine use by the intranasal or intravenous route

        Exclusion Criteria:

          -  Abnormal screening outcome (e.g., ECG, blood chemistry result) that study physicians
             deem clinically significant

          -  Current or past histories of substance abuse or dependence that are deemed by the
             study physicians to interfere with study completion

          -  History of serious physical disease, current physical disease, impaired cardiovascular
             functioning, chronic obstructive pulmonary disease, history of seizure or current or
             past histories of serious psychiatric disorder that in the opinion of the study
             physician would interfere with study participation will be excluded from participation

          -  Females not currently using effective birth control

          -  Contraindications to cocaine, topiramate or phentermine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig R Rush, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Craig R Rush, Ph.D.</last_name>
    <phone>859-257-5388</phone>
    <email>crush2@email.uky.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Kentucky Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William W Stoops, Ph.D.</last_name>
      <phone>859-257-5388</phone>
      <email>william.stoops@uky.edu</email>
    </contact>
    <investigator>
      <last_name>Craig R Rush, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2014</study_first_submitted>
  <study_first_submitted_qc>September 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2014</study_first_posted>
  <last_update_submitted>February 28, 2018</last_update_submitted>
  <last_update_submitted_qc>February 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Craig Rush</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Cocaine</keyword>
  <keyword>Pharmacotherapy</keyword>
  <keyword>Phentermine</keyword>
  <keyword>Topiramate</keyword>
  <keyword>Self-Administration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Phentermine</mesh_term>
    <mesh_term>Topiramate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

